Abstract-Neovascularization is a hallmark feature of retinopathy of prematurity and diabetic retinopathy. Type 1 angiotensin receptor blockade reduces neovascularization in experimental retinopathy of prematurity, known as oxygen-induced retinopathy (OIR). We investigated in OIR whether inhibiting aldosterone with the aldosterone synthase inhibitor FAD286 reduced neovascularization as effectively as angiotensin receptor blockade (valsartan). OIR was induced in neonatal Sprague-Dawley rats, and they were treated with FAD286 (30 mg/kg per day), valsartan (10 mg/kg per day), or FAD286ϩvalsartan. The cellular sources of aldosterone synthase, the mineralocorticoid receptor, and 11␤-hydroxysteroid dehydrogenase 2 were evaluated in retinal cells involved in neovascularization (primary endothelial cells, pericytes, microglia, ganglion cells, and glia). In OIR, FAD286 reduced neovascularization and neovascular tufts by 89% and 67%, respectively, and normalized the increase in vascular endothelial growth factor mRNA (1.74-fold) and protein (4.74-fold) and was as effective as valsartan and FAD286ϩvalsartan. In retina, aldosterone synthase mRNA was reduced with FAD286 but not valsartan. Aldosterone synthase was detected in microglia, ganglion cells, and glia, whereas mineralocorticoid receptor and 11␤-hydroxysteroid dehydrogenase 2 were present in all of the cell types studied. Given the location of aldosterone synthase in microglia and their contribution to retinal inflammation and neovascularization in OIR, the effects of FAD286 on microglial density were studied. The increase in microglial density (ionized calcium binding adaptor protein 1 immunolabeling) in OIR was reduced with all of the treatments. In OIR, FAD286 reduced the increase in mRNA for tumor necrosis factor-␣, intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and monocyte chemoattractant molecule 1. These findings indicate that aldosterone inhibition may be a potential treatment for retinal neovascularization. 
N eovascularization is a hallmark feature of retinopathy of prematurity (ROP) and proliferative diabetic retinopathy, in which the growth of abnormally formed blood vessels leads to hemorrhage and subsequent vision loss and blindness. 1 Retinal neovascularization is a complex process involving not only microvascular cells but also glia and neurons. 2 It is viewed to be largely regulated by the potent angiogenic and permeability factor vascular endothelial growth factor (VEGF). 1 The renin-angiotensin-aldosterone system (RAAS) is implicated in the development of retinal neovascularization, given that a local RAAS exists within the retina, [3] [4] [5] which is upregulated in both ROP and diabetic retinopathy. 6 -8 Furthermore, blockade of angiotensin II with either angiotensin-converting enzyme (ACE) inhibitors or type 1 angiotensin receptor blockers (ARB) have beneficial effects on microvascular injury in experimental ROP 7, 9 and diabetic retinopathy. 10 -13 These protective effects have, to some extent, been translated to clinical studies of diabetic retinopathy, 14 -16 although other randomized, controlled clinical trials have reported ACE inhibition to be ineffective 17 or not superior to other blood pressure-lowering therapies. 18 This shortfall in the retinoprotective effects of ACE inhibition and ARB may indicate that therapies developed for ROP and diabetic retinopathy, which involve the RAAS, may need to consider targeting not only ACE and the type 1 angiotensin receptor but also other RAAS components to improve retinal vascular outcomes.
Aldosterone and its cognate receptor, the mineralocorticoid receptor (MR), are recognized for their role in electrolyte and blood pressure regulation and for influencing heart, kidney, and vascular pathology. 19 -21 Aldosterone production is stimulated by angiotensin II, and it would, therefore, be expected that ACE inhibition or ARB would attenuate the effects of aldosterone. However, in some instances, ACE inhibition and ARB do not reduce aldosterone levels in the long-term because of "aldosterone breakthrough," 22 indicating that aldosterone may be a therapeutic target in diseases that feature overactivity of the RAAS. Current understanding about the role of aldosterone in retinal pathology is limited. We reported previously that MR blockade with spironolactone reduced neovascularization in rats with experimental ROP known as oxygen-induced retinopathy (OIR), whereas aldosterone administration exacerbated retinal neovascularization. 5 In this study, we aimed to determine whether inhibiting the key enzyme in aldosterone production, aldosterone synthase, with FAD286, reduced neovascularization in rats with OIR and was as effective as the ARB valsartan. We also studied whether FAD286 influenced retinal aldosterone synthase and evaluated whether the retinal cell types involved in neovascularization express aldosterone synthase, MR, and 11-␤-hydroxysteroid dehydrogenase 2 (11␤HSD2), the enzyme that confers aldosterone selectivity for the MR.
Materials and Methods

Animals
All of the procedures were performed in Sprague-Dawley rats according to the National Health and Medical Research Council of Australia Guidelines for the Care of Animals in Scientific Research. OIR was induced by exposure between postnatal day (P) 0 to P11 in 80% O 2 cycled with 20% O 2 for 3 hours per day according to a previous method. 5, 23 OIR rats were then placed in room air until P18 (neovascularization period). Shams were rats in room air for the entire study (P0 through P18). Experimental groups were as follows: (1) sham control; (2) shamϩFAD286; (3) OIR control; (4) OIRϩ FAD286; (5) OIRϩvalsartan; and (6) OIRϩFAD286ϩvalsartan. Treatments were administered between P12 and P18 and included the aldosterone synthase inhibitor FAD286 (30 mg/kg per day in sterile saline [pH 7.4], subcutaneous injection; Novartis Pharma) and valsartan (10 mg/kg per day in 0.1 mol/L of Tris buffer [pH 7.4], intraperitoneal injection; Novartis Pharma). Sham and OIR controls received a daily injection of sterile saline (pH 7.4). Rats were killed at P18 with sodium pentobarbitone (170 mg/mL, Virbac, Peakhurst, New South Wales, Australia). Doses of FAD286 and valsartan were based on previous studies indicating amelioration of organ pathology 12, 24 with a concomitant reduction in circulating aldosterone (FAD286) 24 and increase in circulating renin (valsartan), 12 without any detrimental effects on animal health and survival. In the present study, body weight was not influenced by FAD286 and slightly increased by valsartan (in the online-only Data Supplement and Table S1 ). In OIR, preretinal neovascularization, the expression of VEGF and inflammatory factors, and microglial density were evaluated (online-only Data Supplement).
In Vitro Studies
In primary cultures of bovine retinal endothelial cells, bovine retinal pericytes, rat retinal microglia, rat retinal ganglion cells, and rat retinal glia, aldosterone synthase, MR, and 11␤HSD2 were measured. For methods see the online-only Data Supplement and Figure S1 .
Results
FAD286 Reduced Neovascularization
In OIR, but not sham groups, preretinal neovascularization and neovascular tufts were detected (Figures 1 and 2 ). In OIR, FAD286 reduced preretinal neovascularization and neovascular tufts by Ϸ89% and 67%, respectively compared with OIR control (Figures 1 and 2 ). In OIR, valsartan had a similar effect as FAD286, reducing preretinal neovascularization and neovascular tufts by Ϸ76% and 71%, respectively, compared with OIR controls. In OIR, FAD286ϩvalsartan had no additional effect compared with single treatment, reducing preretinal neovascularization, and neovascular tufts by Ϸ75% and 70%, respectively (Figures 1 and 2 ).
FAD286 Reduced Retinal VEGF expression
In sham controls, retinal VEGF mRNA and protein levels were detected and unchanged with FAD286 ( Figure 3) . In OIR controls, VEGF mRNA and protein levels were increased compared with sham groups. In OIR, treatment with either FAD286 or valsartan similarly reduced retinal VEGF mRNA and protein levels compared with OIR control ( Figure  3 ) and with the level of sham control. In OIR, FAD286ϩvalsartan was not more effective in reducing VEGF mRNA compared with either single treatment and did not reduce retinal VEGF protein levels to sham control levels ( Figure 3 ).
FAD286 and Retinal Aldosterone Synthase
Aldosterone synthase mRNA was detected in retina and reduced with FAD286 and FAD286ϩvalsartan but not valsartan alone (Figure 4 ). In the adrenal gland from control animals, FAD286 increased aldosterone synthase mRNA ( Figure 4 ).
Microglia, Rat Retinal Ganglion Cells, and Glia Express Aldosterone Synthase
Aldosterone synthase mRNA was detected in microglia, rat retinal ganglion cells, and glia but not bovine retinal endothelial cells and bovine retinal pericytes ( Figure 5 ). All of the cell types (microglia, rat retinal ganglion cells, glia, bovine retinal endothelial cells, and bovine retinal pericytes) expressed MR and 11␤HSD2 mRNA ( Figure 5 ). Aldosterone synthase, MR, and 11␤HSD2 5 mRNAs were detected in whole retina and adrenal ( Figure 5 and Figure S2 ). 
FAD286 Reduced Microglial Density
In sham controls, ionized calcium binding adaptor protein 1 immunolabeling was sparse and unchanged with FAD286 ( Figure 6 ). In OIR, ionized calcium binding adaptor protein 1 immunolabeling was increased compared with sham groups ( Figure 6 ). In OIR, all of the treatments reduced ionized calcium binding adaptor protein 1 immunolabeling compared with untreated OIR, with valsartan alone slightly more effective ( Figure 6 ).
FAD286 Reduced Retinal Inflammatory Mediators
In sham controls, tumor necrosis factor-␣ (TNF-␣), monocyte chemoattractant molecule-1 (MCP-1), intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 mRNA levels were detected and unchanged with FAD286 ( Figure  S4 ). In OIR controls, retinal TNF-␣, MCP-1, intercellular adhesion molecule-1, and vascular cell adhesion molecule 1 mRNA levels were increased compared with sham groups. In OIR, FAD286 reduced the expression of all factors. In OIR, valsartan was similarly effective as FAD286 in reducing retinal MCP-1 and intercellular adhesion molecule 1 mRNA levels but did not reduce TNF-␣ or vascular cell adhesion molecule 1. In OIR, combination treatment with FAD286ϩvalsartan was similarly effective as FAD286 in reducing retinal TNF-␣, MCP-1, and intercellular adhesion molecule 1 mRNA levels but did not reduce vascular cell adhesion molecule 1 ( Figure S4 ).
Discussion
The major findings of this study are that inhibition of aldosterone synthase with FAD286 reduced key pathogenic features of OIR, including retinal neovascularization, VEGF, the expression of inflammatory mediators, and microglial density, to a similar extent as ARB. The identification of aldosterone synthase, MR, and 11␤HSD2 in retinal glia and ganglion cells suggests that the effects of aldosterone on retinal pathology in OIR may involve these nonvascular cells. . DNA sequencing of PCR products confirmed that aldosterone synthase was amplified and not homologous proteins CYP11B1 and CYP11B3. B, MR was detected in all of the retinal cell types studied and whole retina 5 at the expected molecular weights (rat: 96 bp; bovine: 60 bp). C, 11␤HSD2 was present in RGCs, MG, and G (105 bp); BREC and BRP (99 bp); and whole retina. 5 Larger products of 11␤HSD2 were detected with sequencing indicating that these are potential splice variants. A rat band at 203 bp is homologous to a splice variant of exons 2 and 3 (accession No. AY960975.1). The bovine 11␤HSD2 band at 192 bp contains a sequence 100% homologous to the bovine 11␤HSD2 accession No. but is preceded by a previously unreported sequence, suggesting that this fragment is a previously unreported splice variant of bovine 11␤HSD2. M indicates marker.
The influence of aldosterone on neovascularization, per se, is not widely studied. 25, 26 On the other hand, ACE inhibition and the ability of ARB to reduce neovascularization, vascular leakage, and inflammation in OIR are documented. 7, 23, 27 In previous studies, aldosterone synthase inhibition with FAD286 reduced fibrosis and inflammation in kidney and cardiovascular diseases. 19,20,28 -30 To our knowledge, this is the first report that FAD286 reduced retinal neovascularization and a major angiogenic factor in OIR, VEGF. 1 These findings suggest that aldosterone synthase inhibition could be considered when evaluating potential antiangiogenic treatments for neovascular retinopathies. The finding that the combination of FAD286 and valsartan, provided no additional reduction in retinal neovascularization or VEGF, may be important when considering whether dual blockade has greater benefit for retinopathy compared with monotherapy. However, further studies evaluating the efficacy of lower doses of combined FAD286 and valsartan are required before any conclusions can be drawn. It should be acknowledged that OIR, although a useful model of ROP, does differ from human ROP with retinal neovascularization occurring postnatally rather than prenatally, which may be an important consideration when developing treatment strategies for patients.
Our previous study in OIR indicated that aldosterone has a proangiogenic effect in the retina, with spironolactone reducing retinal neovascularization, VEGF, and inflammation 5 and aldosterone exacerbating retinal vascular pathology. 5 To substantiate these effects, we directly targeted aldosterone production by reducing the synthesis of aldosterone synthase, a key enzyme in aldosterone production. FAD286 is a relatively selective aldosterone synthase inhibitor that is 50 times more selective for reducing plasma aldosterone concentration than plasma corticosterone. 31 The finding that FAD286 reduced retinal neovascularization and inflammation in OIR with a concomitant reduction in retinal aldosterone synthase mRNA suggested that the effects of FAD286 were attributed to a reduction of retinal aldosterone production. However, a limitation of our study was that we cannot comment on whether FAD286 influenced local production of aldosterone, because retinal aldosterone levels were not measured because of the small size of the neonatal retina. We would predict that the effects of FAD286 in OIR are mainly attributed to a reduction of circulating aldosterone levels given that the blood retinal barrier is compromised in OIR, and FAD286 is known to reduce plasma aldosterone levels. 28 FAD286 is known to increase aldosterone synthase expression in the adrenal gland, 29 which is consistent with our findings in the neonatal rat adrenal gland, and may represent a compensatory mechanism that occurs over time in response to reduced circulating aldosterone. Of interest was that FAD286 reduced retinal aldosterone synthase mRNA. The reasons for our findings in retina are not clear, and we cannot assume that a reduction in retinal aldosterone synthase mRNA corresponds with a reduction in retinal aldosterone. It is perhaps important to consider that hypoxia can reduce aldosterone production. 32, 33 In the developing retina, oxygen levels are altered as the retinal vasculature becomes established postnatally. Further changes in oxygen levels are imposed during the hyperoxic and hypoxic periods of OIR. Whether these alterations in retinal oxygen levels directly influenced the effects of FAD286 on retinal aldosterone synthase mRNA levels is unknown and may be of interest to explore in future studies.
Microglia are considered to be the immunocompetent cells of the retina and have a major role in retinal neovascularization via VEGF-related mechanisms and the release of proinflammatory factors. 34 -36 To our knowledge we provide the first evidence that aldosterone synthase is in retinal microglia and not microvascular cells a finding that is consistent with low levels of aldosterone synthase expression in human endothelial cells. 37 Our findings would suggest that retinal microglia are responsive to aldosterone, which is supported by the increased microglial density of OIR, being reduced with FAD286. Furthermore, FAD286 reduced the expression of inflammatory mediators known to be released by microglia in retinopathy, such as TNF-␣ and MCP-1. 36 A limitation of 
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our study was that we did not assess whether FAD286 influenced inflammatory mediators derived from microglia but rather measured mRNA in whole retina. In addition, we did not evaluate whether FAD286 directly influenced microglia-mediated retinal neovascularization. Of interest was that retinal microglia also expressed the type 1 angiotensin receptor ( Figure S3 ), and ARB was effective in reducing microglial density in OIR, a finding that broadens the roles of the type 1 angiotensin receptor to include neovascularization, inflammation, and astrocyte survival and now microglialrelated processes. 5, 7, 23, 38 The presence of aldosterone synthase, MR, and 11␤HSD2 in glia and ganglion cells is also of interest given the contribution of these cell types to OIR 35, 36 and recent evidence that aldosterone influences ion and water channels in macroglial Müller cells. 39 In conclusion, inhibition of aldosterone synthase is equally effective at reducing the retinal neovascularization of OIR as ARB, a finding that highlights the potential of inhibiting aldosterone for the treatment of neovascular retinopathies. Whether FAD286 is as protective as ARB in other aspects of retinal pathology, such as reducing intraocular pressure, 40, 41 is worth investigating in future studies.
Perspectives
It is now apparent that components of the aldosterone system are present in the retina. However, the role(s) of aldosterone in the retina has not been fully explored. Emerging evidence indicates that aldosterone is likely to influence retinal pathology, such as neovascularization, and also normal physiological processes, such as retinal fluid homeostasis. 39 We now await the findings of future studies to elucidate the contribution of aldosterone and the MR to not only vascular events but also glial and neuronal processes in both healthy and diseased retina.
Pre-retinal Neovascularization in oxygen-induced retinopathy (OIR)
Eyes from Sprague Dawley rat pups were processed into paraffin, serially sectioned at 3µm, and every 10 th section stained with haematoxylin and eosin. Five to 10 rats per group were evaluated. Pre-retinal neovascularization was quantitated in 4 non-overlapping fields of retina/section, with 6 sections/retina at least 60µm apart evaluated per rat.
1,2 Pre-retinal neovascularization was defined as an endothelial cell or a blood vessel with a lumen that was protruding into the vitreous cavity while still attached to the retinal surface.
Neovascular Tufts in OIR
Retinal wholemounts were prepared as described previously. 1 Five to 8 rats per group were evaluated. Eyes were enucleated and fixed in 4% paraformaldehyde for 30 minutes. Retinal dissection was performed in a petri-dish filled with 0.1M phosphate buffered saline, pH 7.4 (PBS), under a dissecting microscope. The retina was carefully detached from the choroid using forceps and 4 radial cuts extending about 2/3 from the edge of the retina were made to flatten the retina. The retina was stained with FITC-conjugated Griffonia (Bandeiraea) simplicifolia BS-I lectin (1:100, Sigma-Aldrich, Castle Hill, New South Wales, Victoria, Australia) in 1% Triton X-100 (Sigma-Aldrich) in 0.1M PBS overnight. The retina was then washed with PBS for 6 x 15 minutes and mounted with mounting media (DakoCytomation, Glostrup, Denmark). Individual retinal images were taken at 100x magnification using a digital microscope camera (AxioCam MRc 6.1.0.0, Carl Zeiss, Gottingen, Germany) attached to a Zeiss Axio X1 microscope (Carl Zeiss). Entire retinal montages were achieved using the tiling tool in the AxioObserver software (version 5.3, Carl Zeiss). Neovascular tufts were defined as clumps of blood vessels that were positively labeled for BS-I lectin. Neovascular tufts over the whole retina were psuedocolorized in red, and Image J software (v3.1, National Institutes of Health, Bethesda, Washington, USA) used to set a threshold for red fluorescent labeling, which was then applied to all sections. Neovascular tufts were quantitated over the whole retina and expressed as neovascular tufts per retina.
Real-Time PCR in OIR
Total retinal RNA was isolated using an RNeasy kit (Qiagen, Doncaster, Victoria, Australia) according the manufacturer's protocol. One retina from 6 to 12 rats per group was evaluated. One µg of RNA was subjected to DNase treatment (DNA-free kit, Applied Biosystems, Carlsbad, California, USA) and reverse transcription-PCR (First Strand cDNA synthesis kit, Roche, Switzerland). Primers, probes and cDNA were mixed with the Taqman Universal Master Mix (Applied Biosystems) or SYBR Master Mix (Invitrogen, Carlsbad, California, USA). Real-time PCR was conducted using an ABI 7900 HT Sequence Detection System (Applied Biosystems).
2 mRNA was normalized to 18s rRNA endogenous control and the relative fold difference in expression was calculated using the 2 -ΔΔCt method. 2 The primers for rat tumor necrois factor-α (TNF-α) and vascular cell adhesion molecule-1 (VCAM-1) are as follows: TNF-α forward primer: TGATCGGTCCCAACAAGGA; TNF-α reverse primer: TGGGCTACGGGCTTGTCA;
VCAM-1 forward primer: ACCCAAACAAAGGCAGAGTACAC;
VCAM-1 reverse primer: ACTTGAGCAGGTCAGGTTCACA. The primers and probes for rat 18s, aldosterone synthase (CYP11B2), intercellular adhesion molecule-1, monocyte chemoattractant protein-1 and vascular endothelial growth factor have been previously described. 2 Additionally, aldosterone synthase PCR products were sequenced to confirm specific amplification of aldosterone synthase over CYP11B1 and CYP11B3 which share some homology in the amplified region (see page 6 for more information). CYP11B2 mRNA was detected in 20 cycles.
Enzyme-linked immunosorbent assay (ELISA) in OIR
Retina were dissected and immediately flashed frozen in liquid nitrogen. One retina from 5 to 10 rats per group was evaluated. Retina were homogenized on ice in 0.1M sodium phosphate, pH 7.4, containing protease inhibitor cocktail (Sigma, Castle Hill, NSW, Australia). Lysates were centrifuged at 13000 rpm for 10 minutes at 4°C. Supernatants were collected and the total protein concentration was quantitated using the Bradford colorimetric method (Bio-Rad Laboratories, Gladesville, New South Wales, Australia) according the manufacturer's protocol. Undiluted supernatants were then assayed using a commercially available rat vascular endothelial growth factor ELISA kit (R&D Systems, Minneapolis, Minnesota, USA) All procedures were performed according to the manufacturer's instructions except that the undiluted supernatants were incubated overnight at 4°C.
Immunohistochemistry for the Microglial Marker, Ionized Calcium Binding Adapter Molecule 1 (Iba1) in OIR
Four 3µm paraffin sections at least 60µm apart were randomly selected from each eye, dewaxed in histolene and hydrated in graded ethanol's. Four to 7 rats per group were evaluated. Antigen retrieval was achieved by microwaving in 0.1M citrate buffer for 10 minutes. After washing with PBS, sections were incubated with 1% normal goat serum in PBS for one hour, and then incubated with an anti-Iba-1 antibody (1:1000, Wako, Tokyo, Japan) overnight at 4°C. The sections were washed with PBS and incubated with a biotinconjugated goat anti rabbit IgG (1:200, Dakocytomation) for 30 minutes. After washing with PBS, the sections were then incubated with the Vectastain ABC standard kit (Vector Laboratories, Burlingame, California, USA) for 30 minutes and Liquid DAB + substrate chromagen system (Dakocytomation) for 15 seconds. The sections were then counterstained with Harris' Haematoxylin for 7 minutes, rinsed in tap water, dehydrated through graded ethanols, cleared in histolene and coverslipped with DPX (VWR International Ltd., Poole, England). A negative control without the primary antibody was included to detect nonspecific staining. In each section, 4 non-overlapping fields at x400 magnification were captured using a Spot digital camera (SciTech, Preston, Victoria, Australia). Image J software was used to set a threshold for brown Iba1 immunolabelling, which was then applied to all captured fields. Iba1 immunolabelling was quantitated in the inner retina including pre-retinal vessels using the threshold tool. The inner retina comprised the inner limiting membrane, ganglion cell layer and inner plexiform layer. Results are expressed as Iba1 immunolabelling per field of retina.
Culture of Bovine Retinal Endothelial cells, Bovine Retinal Pericytes and Rat Retinal
Glial Cells. The methods are as described previously.
2,3
Culture of Rat Retinal Microglia
Retinal microglia were isolated as previously described. 4, 5 Retina were collected from Sprague Dawley rat pups at postnatal day 5 and maintained in low-glucose Dulbecco's modified eagle media (DMEM)/2mM L-glutamine/100U penicillin/100µg streptomycin/0.25µg amphotericin B on ice. Retina were washed with Hanks balanced salt solution (HBSS, without Ca 2+ /Mg 2+ ), spun at 1,000 x rpm for 5 minutes, and re-suspended in 0.05% tryspin/0.53mM ethylenediaminetetracetic acid (EDTA, without Ca 2+ /Mg 2+ ) and incubated for 1 hour at 37°C/5% CO 2 , with shaking every 10 minutes. Digestion was quenched with low-glucose DMEM/10% fetal bovine serum (FBS)/100U penicillin/100µg streptomycin/0.25mg amphotericin B, the suspension spun at 1,000 x rpm for 5 minutes and pellet re-suspended in culture medium (low-glucose DMEM, 10% FBS, 100 U penicillin, 100µg streptomycin, 0.25µg amphotericin supplemented with + 1ng/ml mouse granulocyte macrophage colony stimulating factor and plated onto T75 flasks coated with 10µg/ml poly-D-lysine. Cells were cultured until reaching confluence and flasks shaken for 4 hours at 37°C, 200 rpm to separate microglia from astrocytes. After shaking, culture supernatant was removed, spun down at 1,000 rpm for 5 minutes, re-suspended in culture medium, and plated onto either poly-D-lysine coated 6 well plates or coverslips.
Characterization of cultured microglia was performed with immunocytochemistry for the microglial marker, Iba1. 6 Cells were washed twice with HBSS (without Ca 2+ /Mg 2+ ) and fixed with 3.7% formaldehyde in HBSS (without Ca 2+ /Mg 2+ ) at 4°C for 10 minutes. Cells were washed as above and permeabilized with 0.1% Triton X-100 in HBSS (without Ca 2+ /Mg 2+ ) for 5 minutes. After washing as above, cells were blocked with 3% BSA/3% goat serum in HBSS (without Ca 2+ /Mg 2+ ) for 15 minutes. After washing, 2µg/ml rabbit anti-Iba1 in 3% bovine serum albumin (BSA)/3% goat serum in HBSS (without Ca 2+ /Mg 2+ ) was applied and incubated for 2 hours. Cells were washed, then incubated with 1:400 goat anti-rabbit IgGAlexa568 (Invitrogen) in 3% BSA/3% goat serum in HBSS (without Ca 2+ /Mg 2+ ) and incubated for 1 hour. Cells were washed and stained with 4',6'-diamino 2-phenylindole (DAPI, Invitrogen, Victoria Australia) at 300nM in HBSS (without Ca 2+ /Mg 2+ ) for 1 minute, washed again, and mounted (Dako fluorescent mounting medium, Dako) onto slides. Three fields were counted for Iba1 positive cells in duplicate slides. To confirm that cultured cells were microglia, the expression of the microglial marker, cluster of differentiation molecule 11b (CD11b), was measured with real-time PCR and following stimulation with 100U/ml interferon gamma (IFN-γ, Miltenyi, North Ryde, New South Wales, Australia) for 24 hours as described previously. 5 Mouse colony-stimulating factor (5ng/ml, Peprotech, London, United Kingdom) was included both in the IFN-γ and control (without IFN-γ) samples.
Culture of Retinal Ganglion Cells (RGCs)
Retina were dissected from Sprague Dawley rat pups at postnatal day 3 and retained in collection buffer (1mM sodium pyruvate, 10mM Hepes-KOH [pH 7.3], 2mM glutamine, 0.3% BSA, 100U/ml penicillin, 100µg/ml streptomycin) on ice. Retina was centrifuged at 1,000 rpm for 5 minutes at 4°C and the pellet re-suspended in digestion buffer (HBSS, 0.2g/L trypsin, 80U/ml DNase I) for 10 minutes at 37°C with constant agitation. Digestion was quenched by addition of 0.5mg/ml of soybean trypsin inhibitor (Sigma-Aldrich) in HBSS. The retinal cell suspension was centrifuged at 1,000 rpm for 5 minutes at 4°C and resuspended in 0.5mg/ml trypsin inhibitor/2.1mM MgSO 4 in HBSS and the preparation triturated with an 18-gauge blunt-ended needle. The resulting single cell suspension was spun at 1,000 rpm for 5 minutes at 4°C and re-suspended in RGC culture media (Neurobasal media A [Invitrogen], 1×B27 supplement [Invitrogen], 2mM glutamine, 10% dialyzed FBS, 100U/ml penicillin, 100µg/ml streptomycin) and plated onto 10µg/ml poly-D-lysine/50µg/ml laminin coated coverslips or 24 well plates. Experiments were conducted 7 days after isolation. Characterization of RGCs was performed by morphological analysis and immunocytochemistry for the neuronal marker, Thy 1.1. 7 To determine if RGCs were active, sub-confluent RGCs were exposed to 100µM glutamate for 24 hours in Neurobasal A (without phenol red), 1x antioxidant free B27, 2mM glutamine, 100U/ml penicillin, and 100µg/ml streptomycin at 37°C/5%CO 2 . Fifty µl of supernatant was harvested and cytotoxicity measured using a CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega, Victoria, Australia).
Real-time PCR in Cultured Retinal Cells
Retinal endothelial cells, pericytes, glia, microglia and RGCs were cultured and RNA isolated (RNeasy kit, Qiagen). DNA removal and reverse transcription conducted on 1µg of RNA as previously described. 2 Real time PCR was conducted for rat aldosterone synthase, rat (pro)renin receptor, 1 rat angiotensin type 1 receptor, 3 rat and bovine mineralocorticoid receptor and rat and bovine 11β-hydroxysteroid dehydrogenase 2 (11βHSD2) as previously described. 2 The primers and probes for bovine aldosterone synthase are as follows: forward primer:
5'CTCTTCCGCTACACCATCGAA3'; reverse primer: 5'CAAGCCGCTCCCCGTA3'; probe: FAM-labeled MGB 5'CCAGCACCTTAGTCC3'. As a positive control, Sprague Dawley rat adrenal was dissected after euthanasia and homogenized in 600µL RLT buffer (Qiagen RNeasy kit, Qiagen, Victoria, Australia) and total RNA extracted. One µg of RNA was DNase treated and reverse transcribed and real-time PCR conducted as described above. All post real-time run samples were collected, and resolved on a 4% agarose gel to confirm detection of either 11βHSD2, aldosterone synthase or mineralocorticoid receptor PCR product. Real-time PCR was conducted for CD11b mRNA detection using the following primers with SYBR green chemistry, 2 forward primer: 5'GATGCTACTTGGGTTATGCTTC3', reverse primer 5'CGAGGTGCCCAAAACCA3'.
Statistics
Data generated for pre-retinal neovascularization in paraffin sections were subjected to a 1-way ANOVA with a Bonferroni post hoc test. All other data were analyzed by a KruskalWallis test followed by individual Mann-Whitney U tests between groups. Values are mean±SEM. Significance was P<0.05. Investigators were masked to the experimental groups.
Results
Body Weight of Neonatal Rat Pups
Body weight of pups was measured at postnatal day 18. Results are shown in Table S1 . In sham rats, FAD286 had no effect on body weight. In OIR rat pups, body weight was reduced compared to sham rat pups. In OIR pups, FAD286 did not influence body weight compared to OIR control. In OIR, body weight was slightly increased in both valsartan and FAD286+valsartan groups compared to OIR control.
Characterization of rat retinal microglia and rat retinal ganglion cells in culture
Microglia were identified by their immunolabelling for Iba1, with 92% of cells found to be 1ba1 positive ( Figure S1A ). Confirmation that cells were microglia was achieved by the expression of CD11b mRNA ( Figure S1B ). Evidence that cultured microglia were able to be activated was shown with their increased expression of CD11b mRNA following incubation with IFN-γ ( Figure S1B ).
Cells were identified as RGCs by cells having soma of approximately 6µm and long thin neurites ( Figure S1C ). In some areas, RGCs appeared to reside on a feeder layer of glial cells ( Figure S1C ). In addition, cells were positive for Thy 1.1 (not shown). The culture was confirmed to contain RGCs as cell death was significantly increased after exposure to 100µM glutamate ( Figure S1D ), a feature noted in retinal RGCs.
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Aldosterone synthase and the mineralocorticoid receptor are expressed in retina and adrenal Aldosterone synthase was present in primary cultures of RGCs, rat retinal microglia, rat retinal glia and whole retina ( Figure S2 ). DNA sequencing confirmed that this product contained adenine corresponding to position 1128 of rat aldosterone synthase (CYP11B2, NM_012538) in place of an expected guanine for either CYP11B1 (base 1116, NM_012537) or CYP11B3 (base 1116 NM_U17082). The mineralocorticoid receptor was present in all cell types studied (RGCs, microglia, glia, bovine retinal endothelial cells, bovine retinal pericytes) and whole retina ( Figure S2 ). Adrenal gland (A) serves as a positive control ( Figure S2 ). No reverse transcription controls (NRTC) and no template controls (NTC) show no positive signal, indicating the signal in retinal cells, whole retina and adrenal, are from mRNA transcripts.
Components of the renin-angiotensin-aldosterone system are expressed in retinal microglia. As well as aldosterone synthase and the mineralocorticoid receptor, retinal microglia express mRNA for the (pro)renin receptor and the angiotensin type 1 receptor ( Figure S3 ). Table S1 . Body weight of rat pups at postnatal day 18. In shams, FAD286 did not influence the mRNA levels of the inflammatory mediators. In OIR, the mRNA levels of all mediators increased compared to sham groups, and was reduced with FAD286. In OIR, valsartan (Val) was similarly effective as FAD286 in reducing MCP-1 and ICAM-1, but did not reduce TNF-α or VCAM-1. In OIR, FAD286+Val was similarly effective as FAD286 in reducing TNF-α, MCP-1 and ICAM-1, but did not reduce VCAM-1. Mean±SEM. *P<0.01 to sham control. #P<0.05 to OIR control. N=7-12 rats/group.
Tables and Figures
Groups
